Print Page  |  Close Window

Investor Center

Recent Press Releases

Neuralstem Reports Year End 2016 Fiscal Results and Business Update

03/23/17 - Expects to Report NSI-189 Phase 2 major depressive disorder study results in Q3 ahead of schedule GERMANTOWN, Md., March 23, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the dev... More

Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21

03/17/17 - GERMANTOWN, Md., March 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announces that Rich ... More

Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury

03/09/17 - -NSI-566 Achieved Robust Engraftment and Long-Term Survival After Transplantation- - Data Published in Journal of Neurotrauma- GERMANTOWN, Md., March 09, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceu... More

Upcoming Events


There are currently no events scheduled.